🚀 VC round data is live in beta, check it out!
Sanara MedTech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sanara MedTech and similar public comparables like CVRx, Sisram Medical, Inogen, JETEMA Co. and more.
Sanara MedTech Overview
About Sanara MedTech
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Founded
2001
HQ
Employees
141
Website
Financials (LTM)
EV
$224M
Sanara MedTech Financials
Sanara MedTech reported last 12-month revenue of $107M and EBITDA of $17M.
In the same LTM period, Sanara MedTech generated $99M in gross profit, $17M in EBITDA, and had net loss of ($26M).
Revenue (LTM)
Sanara MedTech P&L
In the most recent fiscal year, Sanara MedTech reported revenue of $103M and EBITDA of $17M.
Sanara MedTech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $107M | XXX | $103M | XXX | XXX | XXX |
| Gross Profit | $99M | XXX | $96M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $17M | XXX | $17M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | ($26M) | XXX | ($38M) | XXX | XXX | XXX |
| Net Margin | (24%) | XXX | (36%) | XXX | XXX | XXX |
| Net Debt | — | — | $29M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sanara MedTech Stock Performance
Sanara MedTech has current market cap of $193M, and enterprise value of $224M.
Market Cap Evolution
Sanara MedTech's stock price is $21.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $224M | $193M | 0.0% | XXX | XXX | XXX | $-4.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSanara MedTech Valuation Multiples
Sanara MedTech trades at 2.1x EV/Revenue multiple, and 13.4x EV/EBITDA.
EV / Revenue (LTM)
Sanara MedTech Financial Valuation Multiples
As of April 20, 2026, Sanara MedTech has market cap of $193M and EV of $224M.
Equity research analysts estimate Sanara MedTech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sanara MedTech has a P/E ratio of (7.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $193M | XXX | $193M | XXX | XXX | XXX |
| EV (current) | $224M | XXX | $224M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 13.4x | XXX | 13.2x | XXX | XXX | XXX |
| EV/EBIT | 28.4x | XXX | 24.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | 2.3x | XXX | XXX | XXX |
| P/E | (7.4x) | XXX | (5.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 104.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sanara MedTech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sanara MedTech Margins & Growth Rates
Sanara MedTech's revenue in the last 12 month grew by 13%.
Sanara MedTech's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.6M for the same period.
Sanara MedTech's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sanara MedTech's rule of X is 48% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sanara MedTech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | (5%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 84% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sanara MedTech Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sanara MedTech | XXX | XXX | XXX | XXX | XXX | XXX |
| CVRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Sisram Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Inogen | XXX | XXX | XXX | XXX | XXX | XXX |
| JETEMA Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Deltex Medical Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sanara MedTech M&A Activity
Sanara MedTech acquired XXX companies to date.
Last acquisition by Sanara MedTech was on XXXXXXXX, XXXXX. Sanara MedTech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sanara MedTech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSanara MedTech Investment Activity
Sanara MedTech invested in XXX companies to date.
Sanara MedTech made its latest investment on XXXXXXXX, XXXXX. Sanara MedTech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sanara MedTech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sanara MedTech
| When was Sanara MedTech founded? | Sanara MedTech was founded in 2001. |
| Where is Sanara MedTech headquartered? | Sanara MedTech is headquartered in United States. |
| How many employees does Sanara MedTech have? | As of today, Sanara MedTech has over 141 employees. |
| Who is the CEO of Sanara MedTech? | Sanara MedTech's CEO is Seth D. Yon. |
| Is Sanara MedTech publicly listed? | Yes, Sanara MedTech is a public company listed on Nasdaq. |
| What is the stock symbol of Sanara MedTech? | Sanara MedTech trades under SMTI ticker. |
| When did Sanara MedTech go public? | Sanara MedTech went public in 2020. |
| Who are competitors of Sanara MedTech? | Sanara MedTech main competitors are CVRx, Sisram Medical, Inogen, JETEMA Co.. |
| What is the current market cap of Sanara MedTech? | Sanara MedTech's current market cap is $193M. |
| What is the current revenue of Sanara MedTech? | Sanara MedTech's last 12 months revenue is $107M. |
| What is the current revenue growth of Sanara MedTech? | Sanara MedTech revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Sanara MedTech? | Current revenue multiple of Sanara MedTech is 2.1x. |
| Is Sanara MedTech profitable? | Yes, Sanara MedTech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sanara MedTech? | Sanara MedTech's last 12 months EBITDA is $17M. |
| What is Sanara MedTech's EBITDA margin? | Sanara MedTech's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Sanara MedTech? | Current EBITDA multiple of Sanara MedTech is 13.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.